Comparison of the efficacy and safety of single-pill fixed-dose combinations of losartan/hydrochlorothiazide and valsartan/hydrochlorothiazide in patients with hypertension (SALT-VAT study)

Internal Medicine

Volumn 50, Issue 21, 2011, Pages 2477-2483

  Shiga, Yuhei ^a   Miura, Shin Ichiro ^a   Morii, Joji ^a   Kuwano, Takashi ^a   Mitsutake, Ryoko ^a   Uehara, Yoshinari ^a   Inoue, Asao ^b   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Inoue Hospital   (Japan)

Author keywords

Blood pressure; Hydrochlorothiazide; Losartan; Uric acid; Urinary albumin; Valsartan

Indexed keywords

ALBUMIN; CODIOMD; CREATININE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; PREMINENT; UNCLASSIFIED DRUG; URIC ACID;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MALE; POTASSIUM BLOOD LEVEL; PROTEIN URINE LEVEL; SIDE EFFECT; URIC ACID BLOOD LEVEL;

AGED; BLOOD PRESSURE; DRUG COMBINATIONS; DRUG SUBSTITUTION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 80455129388     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.5939     Document Type: Article

References (18)

1. Dahlöf B, Sever PS, Poulter NR, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet 366: 895-906, 2005.
2. Kato J, Eto T. Diuretics in the LIFE study. Lancet 364: 413, 2004.
3. Ogihara T, Kikuchi K, Matsuoka H, et al; Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 32: 3-107, 2009.
4. Mancia G, De Backer G, Dominiczak A, et al; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25: 1105-1187, 2007.
5. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 25: 217-226, 2007.
6. MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 156: 278-285, 1996.
7. Bickel C, Rupprecht HJ, Blankenberg S, et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 89: 12-17, 2002.
8. Madsen TE, Muhlestein JB, Carlquist JF, et al. Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrol 25: 45-49, 2005.
9. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 19: 999-1007, 2008.
10. Soffer BA, Wright JT Jr, Pratt JH, Wiens B, Goldberg AI, Sweet CS. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 26: 112-117, 1995.
11. Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 25: 1327-1336, 2007.
12. Miura S, Karnik SS, Saku K. Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst 12: 1-7, 2011.
13. Hamada T, Ichida K, Hosoyamada M, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 21: 1157-1162, 2008.
14. Sugihara M, Miura S, Takamiya Y, et al. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation. Hypertens Res 32: 625-630, 2009.
15. Morishita R, Kanda YM, Nakajima M. Irbesartan: Second Generation of ARB as Metabosartan. Curr Hypertens Rev 6: 173-179, 2010.
16. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 79: 733-743, 1989.
17. Ohkubo T, Hozawa A, Yamaguchi J, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens 20: 2183-2189, 2002.
18. Bankir L, Bochud M, Maillard M, Bovet P, Gabriel A, Burnier M. Nighttime blood pressure and nocturnal dipping are associated with daytime urinary sodium excretion in African subjects. Hypertension 51: 891-898, 2008.